l-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial
Aug 2026· Nature Cancer· Vol 7, pp. 1406 - 1418· 0 citations· 37 references
Medicine
Abstract
Exogenous l-glutamine has preclinical antitumor activity although formal clinical translation has not been attempted. We conducted a single-arm phase 1 trial to assess the safety and preliminary efficacy of clinical-grade, US Food and Drug Administration-approved l-glutamine therapy with gemcitabine and nab-paclitaxel (GA) in participants with treatment-naive, advanced pancreatic cancer (n = 16). The primary endpoint was to determine the recommended phase 2 dose (RP2D) by adaptive Bayesian design across standard doses of GA and a dose range of 0.1–0.3 g kg−1 twice-daily oral l-glutamine. Secondary endpoints included safety and preliminary efficacy of the study combination. The primary endpoint was met with the RP2D reached at maximum doses of l-glutamine and GA. The grade ≥3 treatment-related adverse event rate was 66.7%, primarily from GA. Addition of l-glutamine to GA induced tumor shrinkage in 94% of subjects with a best overall response rate (ORR) of 44% (12.5% complete response). Median progression-free survival and overall survival (OS) were 8.5 months (95% confidence interval (CI) 6–not reached (NR)) and 22 months (95% CI 11–NR), respectively. l-Glutamine induced distinct metagenomic and metabolomic signatures on exploratory analyses in glutamine-treated subjects as a single agent, while the combination of l-glutamine and GA nearly doubled the ORR and tripled the OS compared to historical GA alone (ClinicalTrials.gov registration: NCT04634539). In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal adenocarcinoma and determine the recommended phase 2 dose of l-glutamine in combination with gemcitabine and nab-paclitaxel.
BACKGROUND
S-1 has demonstrated non-inferiority to gemcitabine (GEM) in overall survival (OS) in advanced pancreatic cancer and superiority in the adjuvant setting for resectable disease. This study evaluated the efficacy and safety of S-1 combined with GEM plus nab-paclitaxel (nPTX) in advanced pancreatic cancer.
ME...
Yoshiaki Nagatani, N. Chayahara, Hironaga Satake et al.· European Journal of Cancer· 0 citations
The combination of nab-paclitaxel, gemcitabine, and AZD1775 was determined to be too toxic when administered in patients with metastatic or locally advanced, unresectable pancreatic adenocarcinoma.
J. Eads, Ju-Whei Lee, C. Chee et al.· Clinical colorectal cancer· 0 citations
Camrelizumab plus apatinib demonstrated manageable toxicity and preliminary antitumor activity, supporting further investigation of this chemotherapy-free strategy in early-stage TNBC patients with enriched TILs.
Z. Tian, Heng-Yu Li, Yujun Deng et al.· Breast Cancer Research and T...· 0 citations
Findings support the use of paclitaxel oral solution as a viable alternative second-line option for gastric cancer and show a lower incidence of neuropathy, hypersensitivity reactions, alopecia, and musculoskeletal and connective tissue disorders.
J. Li, M. Huang, T. Deng et al.· ESMO Open· 0 citations
Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...
C. Hoyek, C. Eslinger, Angelo Pirozzi et al.· BMC Cancer· 0 citations
PURPOSE
XRD-0394 is a dual ATM/DNA-PK inhibitor designed to increase tumor radiosensitivity. We evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single-dose XRD-0394 administered with palliative radiotherapy (RT) in a first-in-human trial.
PATIENTS AND METHODS
In an open-label, multicenter ph...
Christopher T. Chen, M. Gensheimer, Tona M. Gilmer et al.· International Journal of Rad...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.